SoFi has introduced the SOFIE tokenized bank deposit, a new financial product that represents money held at SoFi Bank. This token offers a yield-bearing deposit with an advertised annual percentage yield (APY) of 4.40%, subject to terms and conditions. The product also features stablecoin conversion, allowing users to convert their deposits into stablecoins. This innovation aims to blend traditional banking with digital asset convenience, potentially attracting investors seeking higher yields and crypto integration.
The Starknet vote on post-quantum Layer-1 research is the story's subject; for readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 23, 2026 23:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 37 rose and 11 fell. Notable movers include BCH (Bitcoin Cash) with a 1-day change of +4.62% and a Pluang order activity of 27% Sell / 73% Buy, VET (VeChain) up +4.43% with balanced buy/sell orders, and ATOM (Cosmos) down with 90% Sell / 10% Buy activity. Prices are Rp5.164.753 for BCH, Rp132 for VET, and Rp32.096 for ATOM.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
